The reason for this is unclear, but we speculate that Endocan may act together with PDGF-BB to maintain a high level of PDGFRa activation in the same tumor region, while other PDGFR ligands are expressed in the different GBM areas and may therefore affect other populations of GBM cells. The gene discussed is ESM1; the disease is neoplasm.